Substance / Medication

Trimetrexate

Overview

Active Ingredient
trimetrexate
RxNorm CUI
42333

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Trimetrexate and folinic acid: a valuable salvage option for Pneumocystis jirovecii pneumonia.
Short Charlotte-Eve S, Gilleece Yvonne C, Fisher Martin J et al. · AIDS · 2009
PMID: 19424049Other
Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate.
Senkovich Olga, Schormann Norbert, Chattopadhyay Debasish · Acta Crystallogr D Biol Crystallogr · 2009
PMID: 19564691Preclinical
A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer.
Matin Khalid, Jacobs Samuel A, Richards Thomas et al. · Am J Clin Oncol · 2005
PMID: 16199980Trial
Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.
Senkovich Olga, Bhatia Vandanajay, Garg Nisha et al. · Antimicrob Agents Chemother · 2005
PMID: 16048931PreclinicalFull text (PMC)
Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
Machiavelli M R, Salum G, Pérez J E et al. · Am J Clin Oncol · 2004
PMID: 15057154Trial
Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase.
Sweeney Colin L, Frandsen Joel L, Verfaillie Catherine M et al. · Cancer Res · 2003
PMID: 12649191Preclinical
Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer.
Garcia Agustin A, Leichman Lawrence, Baranda Joaquina et al. · Int J Gastrointest Cancer · 2003
PMID: 15361639Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Trimetrexate (substance)
SNOMED CT
372899008
UMLS CUI
C0085176
RxNorm CUI
42333

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.